

Boc₂O Mediated Macrolactonisation : Formal Chemoenzymatic Synthesis of Macrolide Antibiotic (-) A26771B[#]

M. Nagarajan

Indian Institute of Chemical Technology, Hyderabad- 500 007, INDIA


Received 23 October 1998; accepted 30 November 1998

Abstract : An efficient, stereocontrolled, formal chemoenzymatic synthesis of macrolide antibiotic A26771B (1) using the improved macrolactonisation reagent, Boc₂O- iPr₂NEt/pyrrolidinopyridine(4-PP) is reported.

© 1999 Published by Elsevier Science Ltd. All rights reserved.

Key words : Macrolides; hydroxylation; enzyme reactions; lactonisation

The sixteen-membered macrolide antibiotic A26771B (1), isolated in 1977 from *penicillium turbatum* was found to be moderately active against gram-positive bacteria, mycoplasma and fungi [1]. Structurally, macrolide A26771B (1) possesses two chiral centres (5*S*,15*R*) and an α,β -unsaturated double bond with a C-4 ketone. Structure elucidation of 1 and assignment of absolute stereochemistry was reported based on




biosynthetic and chemical degradation, NMR studies and Celmer's model [2,3]. The unique biological profile of A26771B (1) has generated tremendous interest among organic chemists and several racemic syntheses [4-9] and a few chiral syntheses [10-12] have been reported. Herein, we report the formal synthesis of the macrolide antibiotic A26771B (1) using Sharpless asymmetric dihydroxylation and enantioselective enzymatic acetylation techniques.

[#] IICT Communication No : 4163

To begin with, our aim was to show the applicability of our recently developed di-*tert*-butyldicarbonate (Boc_2O) mediated macrolactonisation approach[13] for the construction of macrolide A26771B (1) which has so far, been synthesized generally by Yamaguchi macrolactonisation approach [14].

Scheme 1



Reagents : a. MeMgI, ether, 0°C, 2h, 81% b. TBSCl, imidazole, DCM, rt, 5h, 95% c. BH₃.DMS(2M), THF, NaOAc-30%H₂O₂, 0°C, 5h, 75% d. i) PCC-Celite, DCM, rt, 2h, 80% ii) Ph₃P=CHCO₂Et, benzene, reflux, 6h, 85% e. DIBAL-H(1.0eq), toluene, -78°C, 2h then Ph₃P=CHCO₂Et, reflux, 4h, 76%(one pot) f. i) AD-mix- α , MeSO₂NH₂, ^tBuOH-H₂O (1:1), 0°C, 10h, ii) 2,2-dimethoxypropane, acetone, 0.7eq PTSA, 80% g) CRL, isopropenylacetate, hexane, rt, 12h (30% conversion) h) CRL, phosphate buffer (0.05M), pH 7.2, rt, 20h, 69% i) Boc₂O-(β -Pr)₂NEt/pyrrolidino pyridine (4-PP), toluene, 90-95°C, 18h, 80%.


Accordingly, Grignard reaction of 10-undecenal (3) with MeMgI in ether at 0°C afforded the secondary alcohol 4 in 81% yield. Subsequent silyl protection of 4, followed by hydroboration-oxidation of 5 furnished compound 6. The primary hydroxyl group in 6 was oxidized to the aldehyde using PCC and treated with Ph₃P=CHCOOEt in benzene to afford the unsaturated ester 7. The DIBAL-H reduction of 7 at -78°C in toluene, followed by *in situ* Wittig reaction with Ph₃P=CHCOOEt (one-pot) under reflux conditions afforded the conjugated E,E - ester 8¹. Dihydroxylation of 8 at the electron-rich olefin by the Sharpless asymmetric dihydroxylation protocol[15] using AD-mix-α and methane sulphonamide in a 1:1 mixture of *t*-butanol/water afforded the crude diol which was subsequently protected as its acetonide with 2,2-dimethoxypropane in dry acetone and 0.7 eq. of PTSA to provide exclusively the hydroxy ester 9 (80% for two steps).

As enzyme catalysed reactions are becoming routine tools for the resolution of racemic alcohols, the enantioselective acetylation of 9 was envisaged by using *Candida rugosa* lipase[16-20]. Accordingly, alcohol 9 was subjected to acetylation using *Candida rugosa* lipase (CRL, Sigma, type-7, specific activity : 950 units/mg) and isopropenyl acetate in hexane at room temperature to yield the required (R)-acetate¹ 10 {30% conversion, e.e.³ = 89.6% [α]_D²⁵ -9.56 (c,0.62, CHCl₃)} and the unreacted (S)-alcohol 11. The conventional chemical methods for ester hydrolysis using either LiOH or NaOH gave poor yields of the macrolactonisation precursor 12. To circumvent this problem, the (R)-acetate 10 was subjected to enzymatic hydrolysis using CRL in phosphate buffer (0.05M, pH 7.2) at room temperature to furnish the hydroxy acid 12.

1 All the new compounds gave satisfactory spectral data. Spectral data of selected compounds

Compound 8 : IR (neat): 970, 1630, 1710, 2970 cm⁻¹; ¹H NMR (CDCl₃, 200MHz): δ 7.20 (m, 1H), 6.15-6.05 (m, 2H), 5.75 (d, 1H, J=15.6Hz), 4.15 (q, 2H, J=6.8Hz), 3.75 (m, 1H), 2.22-2.08 (m, 2H), 1.50-1.20 (m, 19H), 1.10(d, 3H, J=5.6Hz), 0.85 (s, 9H), 0.05 (s, 6H). 10 : [α]_D - 9.56 (c 0.62, CHCl₃). IR (neat) : 980, 1720, 1735, 2985 cm⁻¹. ¹H NMR (CDCl₃, 200MHz): δ 6.85 (dd, 1H, J = 5.4, 16.0 Hz), 6.10 (d, 1H, J= 16.0 Hz), 4.85 (m,1H), 4.20 (q, 2H, J=6.6Hz), 4.10 (m,1H), 3.70 (m,1H), 2.02 (s,3H), 1.70-1.25 (m, 24H), 1.20 (d,3H,J=5.4Hz), 0.9 (t,3H,J=6.4Hz); EIMS: 397 (M⁺ -CH₃); HRMS Calcd. for C₂₃ H₄₀ O₆ : 397.2580. Found : 397.2583.

§ The stereochemistry and enantiomeric excess of 10 was determined by converting it into the known reported derivative 13 and compared its optical rotation with the literature data [12].



The hydroxy acid **12** was subjected to newly developed macrolactonisation condition using Boc_2O - iPr_2NEt /pyrrolidinopyridine conditions in dry toluene at 90°C to provide the expected macrolide **2** in 80% yield. The spectral and physical data[†] of **2** were found to be in agreement with the data reported in the literature.[10,11] Since, conversion of **2** into antibiotic **1** is already reported in the literature [10,11], the synthesis of **2** formally constitutes the total synthesis of **1**.

In conclusion, an efficient, formal chemoenzymatic synthesis of macrolide antibiotic **1** was achieved in a relatively short reaction sequence and in good overall yield, starting from commercially available 10-undecenal (**3**). The synthesis employs novel macrolactonization conditions using Boc_2O - iPr_2NEt /4-PP without affecting other labile functionalities present in the molecule thereby also demonstrating the versatility and the efficiency of this newly developed process. Application of this new macrolactonisation condition to other complex macrolides is in progress.

Acknowledgements: The author is thankful to Dr. A V Rama Rao, Dr. M K Gurjar and Dr B V Rao for their support and helpful discussions and CSIR, New Delhi for financial support.

References:

1. Michel KH, Demarco PV, Nagarajan R. *J.Antibiotics*. 1977; 30: 571-576.
2. Arai K, Rawlings BJ, Yoshizawa Y, Vederas JC. *J.Am.Chem.Soc.*1989;111:3391-3399.
3. Celmer WD. *Pure.Appl.Chem.*1971; 28:413-453.
4. Hase TA, Nylund EL. *Tetrahedron Lett.* 1979;20:2633-2636.
5. Asaoka M, Abe M, Mukuta T, Takai H. *Chem. Lett.* 1982: 215-218.
6. Trost BM, Brickner SJ. *J. Am. Chem. Soc.*1983; 105: 568-575.
7. Fujisawa T, Okada N, Takeuchi M, Sato T. *Chem. Lett.* 1983: 1271-1272.
8. Bienz S, Hesse M, *Helv.Chim.Acta.* 1987; 70: 1333-1340.
9. Baldwin JE, Adlington RM, Ramcharitar SH. *J.Chem.Soc.,Chem.Commun.*1991: 940-942.
10. Tatsuta K, Nakagawa A, Maruiwa S, Kinoshita M, *Tetrahedron Lett.* 1980;21 :1479-1482.
11. Tatsuta K, Amemiya Y, Kanemura Y, Kinoshita M. *Bull. Chem. Soc. Jpn.* 1982;55: 3248-3253.
12. Sinha SC, Sinha-Bagchi A, Keinar E. *J. Org. Chem.* 1993;27: 7789-7796.
13. Nagarajan M, Kumar VS, Rao BV. *Tetrahedron Lett.*1997;38: 5835-5838 and unpublished results.
14. Inanaga J, Hirata K, Saeki H, Katsuki T, Yamaguchi M. *Bull. Chem. Soc. Jpn.* 1979; 52: 1989-1993.
15. Kolb HC, VanNieuwenhze MS, Sharpless KB. *Chem. Rev.* 1994; 94: 2483-2547
16. Schoffers E, Golebiowski A, Johnson CR. *Tetrahedron*, 1996; 52: 3769-3826.
17. Wong CH, Whitesides GM. *Enzymes in Synthetic Organic Chemistry*, Baldwin, P.D.; Magnus, P.D. (Editors.), *Tetrahedron Organic Chemistry Series*, Vol. 12, Pergamon, 1994.
18. Sharma A, Sankaranarayanan S, Chattopadhyay S, *J.Org. Chem.* 1996;61:1814-1816.
19. Angelis YS, Smomod I, *Tetrahedron Lett.* 1998; 39: 2823-2826.
20. Angelis YS, Smomod I, *Tetrahedron Lett.* 1997; 38: 8109-8112.

[†] **2**: mp: 88-89°C (lit[12] mp : 70-71°C); $[\alpha]_D + 6.79$ (c 1.06, CHCl_3) [lit[12] : $[\alpha]_D + 6.82$ (c 1.75, CHCl_3)]; IR(neat) : 1665, 1715, 2985, 2985 cm^{-1} ; ¹H NMR (CDCl_3 , 400MHz) : δ 6.88 (dd, 1H, J= 6.7, 15.6Hz), 6.13 (d, 1H, J=15.6Hz), 5.05 (m, 1H), 4.15 (dt, 1H, J=1.02, 8.3Hz), 3.75 (m, 1H), 2.31(m, 1H), 2.08(m, 1H), 1.80(m, 1H), 1.65(s, 6H), 1.43(d, 3H, J= 5.6Hz), 1.38-1.18(m, 15H). ¹³CNMR(CDCl_3 , 100MHz): δ 165.48, 144.23, 123.54, 80.73, 79.99, 71.10, 35.23, 30.97, 29.60, 27.77, 27.18, 27.11, 26.89, 26.50, 26.40, 24.74, 23.25, 20.42.EIMS: 324 (M+); HRMS Calcd. for $\text{C}_{19}\text{H}_{32}\text{O}_4$: 324.2301. Found : 324.2297.